Stocks
Adaptive Biotechnologies Financial Statements (ADPT) |
||||||||||
| Adaptive Biotechnologiessmart-lab.ru | % | 2020 | 2021 | 2022 | 2023 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 24.02.2021 | 15.02.2022 | 14.02.2023 | 31.12.2023 | 29.02.2024 | 07.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 98.4 | 154.3 | 185.3 | 170.3 | 170.3 | 171.4 | |||
| Operating Income, bln rub | -152.8 | -209.0 | -200.2 | -201.6 | -201.6 | -191.0 | ||||
| EBITDA, bln rub | ? | -151.1 | -207.3 | -194.4 | -179.4 | -179.4 | -170.8 | |||
| Net profit, bln rub | ? | -139.6 | -205.6 | -142.5 | -225.3 | -225.3 | -236.7 | |||
| OCF, bln rub | ? | -149.7 | -192.7 | -183.9 | 44.5 | -156.3 | -101.2 | |||
| CAPEX, bln rub | ? | 18.8 | 61.7 | 16.3 | 0.000 | 10.7 | 5.59 | |||
| FCF, bln rub | ? | -168.5 | -254.5 | -200.3 | 44.5 | -167.0 | -106.8 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 228.7 | 314.0 | 327.6 | 294.6 | 274.1 | 279.9 | ||||
| Cost of production, bln rub | 22.5 | 49.3 | 57.9 | 77.3 | 97.8 | 82.5 | ||||
| R&D, bln rub | 116.1 | 142.3 | 141.8 | 122.1 | 101.6 | 111.3 | ||||
| Interest expenses, bln rub | 0.000 | 0.000 | 4.24 | 13.8 | 13.8 | 12.7 | ||||
| Assets, bln rub | 1 116 | 923.3 | 856.6 | 661.1 | 661.1 | 620.3 | ||||
| Net Assets, bln rub | ? | 743.3 | 604.0 | 464.2 | 308.3 | 308.4 | 274.9 | |||
| Debt, bln rub | 107.9 | 111.7 | 108.0 | 98.8 | 229.4 | 96.5 | ||||
| Cash, bln rub | 688.3 | 353.1 | 498.2 | 346.4 | 346.4 | 308.9 | ||||
| Net debt, bln rub | -580.4 | -241.3 | -390.2 | -247.6 | -117.0 | -212.4 | ||||
| Ordinary share price, rub | 59.1 | 28.1 | 7.64 | 4.90 | 4.90 | 4.87 | ||||
| Number of ordinary shares, mln | 131.2 | 140.4 | 142.5 | 144.4 | 144.4 | 145.8 | ||||
| Market cap, bln rub | 7 759 | 3 938 | 1 089 | 707 | 707 | 710 | ||||
| EV, bln rub | ? | 7 178 | 3 697 | 699 | 460 | 591 | 498 | |||
| Book value, bln rub | 614 | 476 | 338 | 189 | 184 | 151 | ||||
| EPS, rub | ? | -1.06 | -1.46 | -1.00 | -1.56 | -1.56 | -1.62 | |||
| FCF/share, rub | -1.28 | -1.81 | -1.41 | 0.31 | -1.16 | -0.73 | ||||
| BV/share, rub | 4.68 | 3.39 | 2.37 | 1.31 | 1.28 | 1.04 | ||||
| EBITDA margin, % | ? | -153.6% | -134.3% | -104.9% | -105.3% | -105.3% | -99.7% | |||
| Net margin, % | ? | -141.9% | -133.2% | -76.9% | -132.3% | -132.3% | -138.1% | |||
| FCF yield, % | ? | -2.17% | -6.46% | -18.4% | 6.28% | -23.6% | -15.0% | |||
| ROE, % | ? | -18.8% | -34.0% | -30.7% | -73.1% | -73.0% | -86.1% | |||
| ROA, % | ? | -12.5% | -22.3% | -16.6% | -34.1% | -34.1% | -38.2% | |||
| P/E | ? | -55.6 | -19.2 | -7.64 | -3.14 | -3.14 | -3.00 | |||
| P/FCF | -46.1 | -15.5 | -5.44 | 15.9 | -4.24 | -6.65 | ||||
| P/S | ? | 78.9 | 25.5 | 5.88 | 4.15 | 4.15 | 4.14 | |||
| P/BV | ? | 12.6 | 8.27 | 3.22 | 3.74 | 3.84 | 4.69 | |||
| EV/EBITDA | ? | -47.5 | -17.8 | -3.59 | -2.56 | -3.29 | -2.91 | |||
| Debt/EBITDA | 3.84 | 1.16 | 2.01 | 1.38 | 0.65 | 1.24 | ||||
| R&D/CAPEX, % | 617.3% | 230.5% | 867.1% | 949.7% | 1 992% | |||||
| CAPEX/Revenue, % | 19.1% | 40.0% | 8.82% | 0.00% | 6.28% | 3.26% | ||||
| Adaptive Biotechnologies shareholders | ||||||||||
